Inhalable Drugs Market Analysis

Drug Form (Aerosol, Dry Powder Formulation, Spray)

The dry powder formulation segment in the inhalable drugs market is anticipated to hold a revenue share of 34.9% through 2037 owing to their quick effectiveness and patient comfort. Dry powder formulations are targeting solutions that deliver medications directly to the lungs, allowing for rapid absorption into the bloodstream. This direct delivery is crucial for managing respiratory diseases such as asthma and COPD as it quickly and effectively alleviates symptoms such as wheezing and shortness of breath. Dry drug formulations offer several benefits such as improved patient care owing to their easier administration and better stability compared to liquid formulations. Some of the pure powder drug formulations available in the inhalable drugs market are AstraZeneca's Bricanyl Turbuhaler, Pulmicort Turbuhalers, and Teva Pharmaceutical Industries Ltd’s Adasuve.

Application (Respiratory Diseases, Non-respiratory Diseases)

The respiratory diseases segment is forecasted to account for 76.5% of the global inhalable drugs market share through 2037.  The increasing cases of respiratory disorders such as occupational lung diseases, COPD, and asthma worldwide are pushing the demand for advanced inhalable medications. High intake of toxic substances such as tobacco and alcohol, air pollution, and allergic chemicals and drugs primarily contribute to respiratory diseases. For instance, according to the Institutes of Health Metrics and Evaluation, in 2019, the prevalence of chronic respiratory diseases was around 454.6 million cases globally. The trend towards combination inhalers such as steroids with long-acting bronchodilators that offer enhanced therapeutic is contributing to the segmental growth.

Our in-depth analysis of the inhalable drugs market includes the following segments: